To further explore the mechanism by which TY ameliorates RA, we verified the core targets predicted by network pharmacology, including PI3K, AKT1, TNF‐α, IL‐1β, IL‐6, MMPs, and TIMP1. The gene discussed is IL1B; the disease is rheumatoid arthritis.